Design of a protease‐activated PD‐L1 inhibitor
Sign Up to like & getrecommendations! Published in 2023 at "Protein Science"
DOI: 10.1002/pro.4578
Abstract: Immune checkpoint inhibitors that bind to the cell surface receptor PD‐L1 are effective anti‐cancer agents but suffer from immune‐related adverse events as PD‐L1 is expressed on both healthy and cancer cells. To mitigate toxicity, researchers… read more here.
Keywords: protease; activated inhibitor; protease activated; inhibitor ... See more keywords